Why Insmed (INSM) Is Up 5.4% After FDA Approves First Oral NCFB Therapy BRINSUPRI

• On August 12, 2025, Insmed Incorporated announced that the U.S. FDA approved BRINSUPRI (brensocatib), the first and only FDA-approved oral therapy for non-cystic fibrosis bronchiectasis in adults and children 12 years and older, with Maxor Specialty Pharmacy later selected as a limited distribution provider.
• This approval not only introduces a first-in-class treatment for an underserved patient population but also positions Insmed to potentially establish a new standard of care for approximately 500,000 diagnosed individuals in the U.S. alone.
• We'll examine how BRINSUPRI's FDA approval as the first NCFB therapy could shift Insmed's investment outlook and market opportunity.

Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

Insmed Investment Narrative Recap

For an investor to remain confident in Insmed, belief in the company's ability to turn scientific innovation, like the FDA approval of BRINSUPRI, into sustained commercial success is essential. This approval significantly de-risks the most important short-term catalyst: the US launch of brensocatib. However, risks remain around how quickly payers will cover the therapy and actual patient uptake, which could materially impact revenue momentum in the near term.

Among the latest announcements, the partnership with Maxor Specialty Pharmacy as a limited distribution provider for BRINSUPRI stands out. This step aims to streamline market access and may help Insmed address challenges related to swift product uptake, tying directly into the company's short-term commercial goals as it brings its first-in-class therapy to market.

On the other hand, investors should be aware that unexpected hurdles in payer negotiations could still create...

Read the full narrative on Insmed (it's free!)

Insmed's narrative projects $1.9 billion revenue and $293.8 million earnings by 2028. This requires 72.0% yearly revenue growth and a $1,207.6 million increase in earnings from -$913.8 million.

Uncover how Insmed's forecasts yield a $120.12 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community members estimate Insmed’s fair value from US$120.12 to US$21,337.07. With brensocatib's FDA approval, how payers respond may prove just as influential as clinical results.

Explore 3 other fair value estimates on Insmed - why the stock might be a potential multi-bagger!

Build Your Own Insmed Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Insmed research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Insmed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insmed's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com